Company Filing History:
1 out of 23 
1 out of 5 Years Active: 2025
Title: Young-Joo Ahn: Innovator in Growth Hormone Treatment
Introduction
Young-Joo Ahn is a notable inventor based in Seongnam-si, South Korea. He has made significant contributions to the field of medicine, particularly in the treatment of growth hormone deficiency. His innovative approach has led to the development of a unique method that utilizes a human growth hormone fusion protein.
Latest Patents
Young-Joo Ahn holds a patent for a method for treating growth hormone deficiency employing a human growth hormone fusion protein known as GX-H9. This method involves administering a pharmaceutical composition containing the hGH fusion protein along with a pharmaceutically acceptable carrier. The administration can occur once a week at a dose of 0.4 to 1.6 mg per kilogram of body weight for pediatric patients, or once every two weeks at a dose of 0.8 to 3.2 mg per kilogram of body weight.
Career Highlights
Throughout his career, Young-Joo Ahn has worked with prominent companies in the biotechnology sector, including Genexine, Inc. and Handok Inc. His work has focused on advancing therapeutic methods that improve patient outcomes in growth hormone-related conditions.
Collaborations
Young-Joo Ahn has collaborated with various professionals in his field, including his coworker Jung Won Woo, who has contributed to his research and development efforts.
Conclusion
Young-Joo Ahn's innovative work in the treatment of growth hormone deficiency showcases his dedication to improving healthcare solutions. His patent for the hGH fusion protein method represents a significant advancement in pediatric medicine.